logo
logo

Symvivo Corporation Receives Funding for COVID-19 Vaccine Program

Oct 20, 2020•over 4 years ago

Amount Raised

$2 Million

Round Type

seed

Burnaby

Description

Symvivo Corporation today announced that it is receiving advisory services and funding of up to $2.8 million from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the clinical advancement of bacTRL-Spike™, the company’s oral, room temperature-stable DNA vaccine candidate for the prevention of COVID-19.

Company Information

Company

Symvivo

Location

Burnaby, British Columbia, Canada

About

Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site specific delivery of genes for the treatment and prevention of disease. Symvivo’s bacTRL platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient’s own cells to produce therapeutic proteins. Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology, immunology and gene replacement. Symvivo is headquartered in Burnaby BC. For more information visit www.Symvivo.com.

FundzWatch™ Score

60
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood